Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial

BACKGROUND: Nanoliposomal irinotecan (nal-IRI) was recently authorized in Japan for unresectable pancreatic cancer after disease progression following chemotherapy. Physicians now consider certain aspects of nal-IRI safety profile as slightly different from conventional irinotecan. This report aims...

Descripción completa

Detalles Bibliográficos
Autores principales: Furuse, Junji, Ueno, Makoto, Ikeda, Masafumi, Okusaka, Takuji, Teng, Zhaoyang, Furuya, Momoko, Ioka, Tatsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885735/
https://www.ncbi.nlm.nih.gov/pubmed/36412114
http://dx.doi.org/10.1093/jjco/hyac177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885735/
https://www.ncbi.nlm.nih.gov/pubmed/36412114
http://dx.doi.org/10.1093/jjco/hyac177

Ejemplares similares